ArticleScientific reports2026
Cervi-LLM for real time colposcopy lesion detection and interpretable diagnosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Colposcopy, a key procedure in cervical cancer screening for patients with abnormal TCT or HPV test results, requires extensive training for accurate diagnosis, yet diagnostic performance varies significantly across regions. This study presents Cervi-LLM, a multimodal MoE framework designed to assist in colposcopic detection by providing precise lesion localization and stratified diagnoses. The dataset included 126 cervical cancer, 692 HSIL, 306 LSIL, and 999 normal cases. Cervi-LLM integrates three core components: 1) YOLOMed for real-time, multi-scale segmentation of three staining modalities (saline, acetic acid, iodine); 2) joint fine-tuning of a LLM on both image features and clinical text using LoRA and progressive unfreezing; and 3) a two-level MoE architecture that fuses rule-based and data-driven expert outputs via dynamic gating, calibrated with clinical rules to deliver interpretable diagnoses (Normal/LSIL/HSIL( +)). In segmentation, Cervi-LLM achieved PA of 94.51% and meanIoU of 78.23%, outperforming U-Net (91.83%, 72.76%) and Polyp-PVT (93.69%, 75.34%). For three-class classification, it reached an overall ACC of 91.52%, exceeding junior physicians (65.88%) and senior physicians (76.57%). In detecting HSIL( +), it achieved sensitivity of 95.96% and specificity of 94.17%, compared to 67.58% and 81.67% for the senior physicians. The system processes images at approximately 30 fps and delivers a final diagnosis in 0.30 ± 0.05 min. Cervi-LLM effectively overcomes conventional colposcopy limitations, offering an accurate, real-time intelligent tool for cervical lesion screening and biopsy guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.